This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Janssen, Johnson & Johnson partly prevail in counterfeit HIV drug row

( April 1, 2025, 18:18 GMT | Official Statement) -- MLex Summary: Defendants who participated in a criminal conspiracy to sell black-market HIV medicines made by Janssen Sciences and Johnson & Johnson were denied a summary judgment of no liability under the Lanham Act, but in the same ruling US Judge Brian Cogan of the Eastern District of New York also dealt the drugmakers several blows. According to the judge, whether Janssen and J&J made use of pedigrees — transactional data required by the federal Food, Drug and Cosmetic Act — as part of their quality control procedures sufficient to render alterations of the data by the defendants actionable will need to be decided by jurors.See attached document....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections